Scholarlink

<p>Women globally spend a significant portion of their lives experiencing perimenopausal and menopausal symptoms, which can severely affect their quality of life. Hormone Replacement Therapy (HRT) has proven effective in alleviating symptoms such as hot flushes, sleep disturbances, and mood disorders. However, disparities in access to HRT exist, especially in low- and middle-income countries (LMICs), where socioeconomic factors and healthcare availability may limit treatment access. We aimed to explore economic barriers and disparities to access to HRT across Brazil, Ghana, Malaysia, Nepal, Nigeria and Sri Lanka. A cross-sectional exploratory study was conducted using publicly available data from national healthcare databases, pharmacies, and hospital formularies from Brazil, Ghana, Malaysia, Nepal, Nigeria, and Sri Lanka. The availability and cost of common HRT medicines, including oral and transdermal therapies, were analysed alongside of surgical procedures. Affordability was assessed by comparing the cost of a two-month HRT supply to the number of days of minimum wage work required to cover the cost. Additionally, Gross National income per capita was also collected to contextualise these findings. The availability of HRT medicines varied widely across six countries, with Brazil and Nigeria offering a broader range of options compared to Ghana and Nepal. Pricing disparities were significant, with the cost of medicines such as the Mirena Coil requiring over 21&#xa0;days of minimum wage work in Brazil and more than 260&#xa0;days in Nigeria for Angeliq. Affordability remained a critical issue across LMICs, with high out-of-pocket costs restricting access to essential menopausal treatments. This study reveals substantial economic barriers to accessing HRT in LMICs, driven by high costs and limited availability. Healthcare policy reforms to improve access and affordability of HRT in these regions are urgently needed. These findings can inform strategies to reduce healthcare inequalities and enhance women’s health outcomes globally.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A perspective on economic barriers and disparities in access to hormone replacement therapy in LMICs (MARIE-WP2b)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月26日

查看全文
  • Gayathri Delanerolle,
  • Snehal Ghosh,
  • Paula Briggs,
  • Peter Phiri,
  • Julie Taylor,
  • Vindya Pathiraja,
  • Tharanga Mudalige,
  • Yassine Bouchareb,
  • Heitor Cavalini,
  • Sharron Hinchliff,
  • Carol Atkinson,
  • Kristina Potocnik,
  • Lucky Saraswat,
  • Fred Tweneboah-Koduah,
  • Nana Afful-Mintah,
  • Helen Felicity Kemp,
  • George Uchenna Eleje,
  • Divinefavour Echezona Malachy,
  • Bernard Mbwele,
  • Teck-Hock Toh,
  • Jude Siong Yip-King,
  • Daniela Angerame Yela,
  • Gabriela Pravatta Rezende,
  • Renan Massao Nakamura,
  • Cristina Laguna Benetti-Pinto,
  • Muhammad Irfan,
  • Rabia Kareem,
  • Jeremy van Vlymen,
  • Ashish Shetty,
  • Ganesh Dangal,
  • Suman Pant,
  • Kathleen Riach,
  • Nirmala Rathnayake,
  • Lanka Dasanayake,
  • Jian Qing Shi,
  • Om Kurmi,
  • Saval Khanal,
  • Sohier Elneil

摘要

Women globally spend a significant portion of their lives experiencing perimenopausal and menopausal symptoms, which can severely affect their quality of life. Hormone Replacement Therapy (HRT) has proven effective in alleviating symptoms such as hot flushes, sleep disturbances, and mood disorders. However, disparities in access to HRT exist, especially in low- and middle-income countries (LMICs), where socioeconomic factors and healthcare availability may limit treatment access. We aimed to explore economic barriers and disparities to access to HRT across Brazil, Ghana, Malaysia, Nepal, Nigeria and Sri Lanka. A cross-sectional exploratory study was conducted using publicly available data from national healthcare databases, pharmacies, and hospital formularies from Brazil, Ghana, Malaysia, Nepal, Nigeria, and Sri Lanka. The availability and cost of common HRT medicines, including oral and transdermal therapies, were analysed alongside of surgical procedures. Affordability was assessed by comparing the cost of a two-month HRT supply to the number of days of minimum wage work required to cover the cost. Additionally, Gross National income per capita was also collected to contextualise these findings. The availability of HRT medicines varied widely across six countries, with Brazil and Nigeria offering a broader range of options compared to Ghana and Nepal. Pricing disparities were significant, with the cost of medicines such as the Mirena Coil requiring over 21 days of minimum wage work in Brazil and more than 260 days in Nigeria for Angeliq. Affordability remained a critical issue across LMICs, with high out-of-pocket costs restricting access to essential menopausal treatments. This study reveals substantial economic barriers to accessing HRT in LMICs, driven by high costs and limited availability. Healthcare policy reforms to improve access and affordability of HRT in these regions are urgently needed. These findings can inform strategies to reduce healthcare inequalities and enhance women’s health outcomes globally.